Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 5
Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease
A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.
Video content above is prompted by the following:
Briefly discuss second-line (2L) treatment of DLBCL.
- What are preferred regimens for transplant ineligible versus transplant eligible?
- What are preferred regimens for patients that relapse within 12 months versus those that do not progress within 12 months?